Clinical Trial Update: Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial assessing a skin toxicity treatment in metastatic colorectal cancer patients treated with panitumumab plus irinotecan-based therapy, with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Camptosar (irinotecan)
• Panitumumab (panitumumab)

Snippet

Sponsor: Amgen | Conditions: Metastatic Colorectal Cancer, Skin Rash | Phase 2 | Status: COMPLETED | Results posted: 2016-02-23